These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

53 related articles for article (PubMed ID: 20934441)

  • 1. Inhibition of phospholipase A2 increased the removal of the prion derived peptide PrP82-146 from cultured neurons.
    Bate C; Ingham V; Williams A
    Neuropharmacology; 2011; 60(2-3):365-72. PubMed ID: 20934441
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A glycosylphosphatidylinositol analogue reduced prion-derived peptide mediated activation of cytoplasmic phospholipase A2, synapse degeneration and neuronal death.
    Bate C; Tayebi M; Williams A
    Neuropharmacology; 2010; 59(1-2):93-9. PubMed ID: 20398681
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Amyloid-β(1-40) inhibits amyloid-β(1-42) induced activation of cytoplasmic phospholipase A2 and synapse degeneration.
    Bate C; Williams A
    J Alzheimers Dis; 2010; 21(3):985-93. PubMed ID: 20634578
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phospholipase A2 inhibitors protect against prion and Abeta mediated synapse degeneration.
    Bate C; Tayebi M; Williams A
    Mol Neurodegener; 2010 Apr; 5():13. PubMed ID: 20374666
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Squalestatin alters the intracellular trafficking of a neurotoxic prion peptide.
    Wilson R; Bate C; Boshuizen R; Williams A; Brewer J
    BMC Neurosci; 2007 Nov; 8():99. PubMed ID: 18034899
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Docosahexaenoic and eicosapentaenoic acids increase neuronal death in response to HuPrP82-146 and Abeta 1-42.
    Bate C; Marshall V; Colombo L; Diomede L; Salmona M; Williams A
    Neuropharmacology; 2008 May; 54(6):934-43. PubMed ID: 18355880
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Platelet-activating factor antagonists protect amyloid-beta damaged neurons from microglia-mediated death.
    Bate C; Kempster S; Williams A
    Neuropharmacology; 2006 Aug; 51(2):173-81. PubMed ID: 16678220
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Polyunsaturated fatty acids protect against prion-mediated synapse damage in vitro.
    Bate C; Tayebi M; Salmona M; Diomede L; Williams A
    Neurotox Res; 2010 Apr; 17(3):203-14. PubMed ID: 19644728
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sublethal concentrations of prion peptide PrP106-126 or the amyloid beta peptide of Alzheimer's disease activates expression of proapoptotic markers in primary cortical neurons.
    White AR; Guirguis R; Brazier MW; Jobling MF; Hill AF; Beyreuther K; Barrow CJ; Masters CL; Collins SJ; Cappai R
    Neurobiol Dis; 2001 Apr; 8(2):299-316. PubMed ID: 11300725
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of phospholipase A2 increases tau phosphorylation at Ser214 in embryonic rat hippocampal neurons.
    De-Paula VJ; Schaeffer EL; Talib LL; Gattaz WF; Forlenza OV
    Prostaglandins Leukot Essent Fatty Acids; 2010 Jan; 82(1):57-60. PubMed ID: 19726172
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Humanin rescues cortical neurons from prion-peptide-induced apoptosis.
    Sponne I; Fifre A; Koziel V; Kriem B; Oster T; Pillot T
    Mol Cell Neurosci; 2004 Jan; 25(1):95-102. PubMed ID: 14962743
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The glycosylphosphatidylinositol anchor is a major determinant of prion binding and replication.
    Bate C; Tayebi M; Williams A
    Biochem J; 2010 Apr; 428(1):95-101. PubMed ID: 20196773
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fibrillar prion peptide PrP(106-126) treatment induces Dab1 phosphorylation and impairs APP processing and Abeta production in cortical neurons.
    Gavín R; Ureña J; Rangel A; Pastrana MA; Requena JR; Soriano E; Aguzzi A; Del Río JA
    Neurobiol Dis; 2008 May; 30(2):243-54. PubMed ID: 18374587
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phospholipase A2 inhibitors or platelet-activating factor antagonists prevent prion replication.
    Bate C; Reid S; Williams A
    J Biol Chem; 2004 Aug; 279(35):36405-11. PubMed ID: 15210691
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An in vitro model for synaptic loss in neurodegenerative diseases suggests a neuroprotective role for valproic acid via inhibition of cPLA2 dependent signalling.
    Williams RS; Bate C
    Neuropharmacology; 2016 Feb; 101():566-75. PubMed ID: 26116815
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cholesterol esterification reduces the neurotoxicity of prions.
    Bate C; Tayebi M; Williams A
    Neuropharmacology; 2008 Jun; 54(8):1247-53. PubMed ID: 18448139
    [TBL] [Abstract][Full Text] [Related]  

  • 17. α-Synuclein-induced synapse damage in cultured neurons is mediated by cholesterol-sensitive activation of cytoplasmic phospholipase A2.
    Bate C; Williams A
    Biomolecules; 2015 Mar; 5(1):178-93. PubMed ID: 25761116
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prion peptide induces neuronal cell death through a pathway involving glycogen synthase kinase 3.
    Pérez M; Rojo AI; Wandosell F; Díaz-Nido J; Avila J
    Biochem J; 2003 May; 372(Pt 1):129-36. PubMed ID: 12578563
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cellular cholesterol enrichment prevents prion peptide-induced neuron cell damages.
    Jeong JK; Seol JW; Moon MH; Seo JS; Lee YJ; Kim JS; Park SY
    Biochem Biophys Res Commun; 2010 Oct; 401(4):516-20. PubMed ID: 20875400
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of platelet activating factor in prion and amyloid-beta neurotoxicity.
    Bate C; Salmona M; Williams A
    Neuroreport; 2004 Mar; 15(3):509-13. PubMed ID: 15094513
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.